Researchers uncover the source of cells that contribute to pulmonary fibrosis
Researchers have been trying for decades to stop the cells that damage the lung in people with pulmonary fibrosis. Now a team ...
Vertex Pharmaceuticals' SWOT analysis: biotech giant's stock faces growth challenges
Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biotechnology company known for its cystic fibrosis (CF) treatments, is at a critical juncture as it seeks to diversify its portfolio and maintain its ...
BioSpace2d
Cystic Fibrosis Biotech Sionna Announces $150M IPO
The Massachusetts-based biotech plans to use the funds to push its candidates into mid-stage clinical trials in a space ...
Vertex Pharmaceuticals' SWOT analysis: cystic fibrosis leader faces pipeline challenges
Vertex Pharmaceuticals (NASDAQ:VRTX), a global biotechnology company with a market capitalization of $119.1 billion known for its transformative cystic fibrosis (CF) treatments, finds itself at a ...